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LIVER DISEASE
Metronidazole and Ursodeoxycholic Acid for
Primary Sclerosing Cholangitis: A Randomized
Placebo-Controlled Trial
Martti Färkkilä,1 Anna-Liisa Karvonen,2 Heimo Nurmi,3 Hannu Nuutinen,1 Matti Taavitsainen,4
Pekka Pikkarainen,2 and Päivi Kärkkäinen5
No effective medical therapy is currently available for primary sclerosing cholangitis (PSC).
Ursodeoxycholic acid (UDCA) improves liver enzymes, but its effect on liver histology is
controversial. Metronidazole (MTZ) prevents PSC-like liver damage in animal models and
reduces intestinal permeability. We recruited 80 patients with PSC into a randomized
placebo-controlled study to evaluate the effect of UDCA and MTZ (UDCA/MTZ) compared
with UDCA/placebo on the progression of PSC. Patients (41 UDCA/placebo and 39 UDCA/
MTZ) were followed every third month. Assessment of liver function test, histological stage
and grade, and cholangiography (via ERCP) at baseline showed no differences between the
groups. After 36 months, serum aminotransferases -glutamyltransferase, and alkaline
phosphatase (ALP) decreased markedly in both groups, serum ALP more significantly in the
UDCA/MTZ group (337  54 U/L, P < .05) compared with the UDCA/placebo group.
The New Mayo Risk Score decreased markedly only in the UDCA/MTZ group (0.50 
0.13, P < .01). The number of patients with improvement of stage (P < .05) and grade (P <
.05) was higher in the combination group. ERCP findings showed no progression or im-
provement in 77% and 68% of patients on UDCA/MTZ and UDCA/placebo, respectively.
In conclusion, combining MTZ with UDCA in PSC improved serum ALP levels and New
Mayo Risk Score, but no statistically significant effect on disease progression as assessed via
liver histology or ERCP was seen. Long-term studies using a higher dose of UDCA combined
with MTZ in larger patient populations are indicated. (HEPATOLOGY 2004;40:1379–1386.)
Primary sclerosing cholangitis (PSC) is a progressivecholestatic liver disease of unknown etiology char-acterized by inflammation and fibrosis of the intra-
and extrahepatic bile ducts.1 Approximately 80% of pa-
tients have concomitant inflammatory bowel disease,
most commonly ulcerative colitis. The strong association
between PSC and inflammatory bowel disease has been
speculated to cause increased translocation of colonic bac-
teria and endotoxins, as well as enhanced absorption of
toxic bile acids to the liver via the portal vein.1,2 This may
lead to activation of Kupffer cells in the liver, with conse-
quent overproduction of tumor necrosis factor and im-
munoactivation of biliary epithelial cells in genetically
susceptible patients.2,3 A close genetic association of PSC
with HLA-DR3, DQ2 has been reported4 and is de-
scribed in other autoimmune liver diseases, as well.5
Moreover, in PSC biliary epithelial cells have demon-
strated strong immunostaining for endotoxin.6 In rats,
overproduction of tumor necrosis factor has been associ-
ated with bile duct destruction and proliferation,7,8 and
Abbreviations: PSC, primary sclerosing cholangitis; UDCA, ursodeoxycholic
acid; MTZ, metronidazole; ERCP, endoscopic retrograde cholangio-pancreatico-
graphy; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate
aminotransferase.
From the 1Division of Gastroenterology, Department of Medicine, and 5Depart-
ment of Pathology, Helsinki University Central Hospital, Finland; 2Department of
Medicine, Division of Gastroenterology, Tampere University Central Hospital,
Tampere, Finland; 3Department of Medicine, Division of Gastroenterology, Turku
University Central Hospital, Turku, Finland; 4Medivire, Ruoholahti, Itämeren-
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the self-filling loops of the small bowel associated with
bacterial overgrowth with Bacteroides species can lead to
hepatobiliary injury resembling PSC in humans.9
Liver damage can be prevented with metronidazole
(MTZ) or tetracycline.9 In humans, metronidazole has
been shown to induce significant inhibition of the endo-
toxin-stimulated tumor necrosis factor alpha production
of human peripheral blood mononuclear cells at thera-
peutic levels.10 Metronidazole also has beneficial effects in
healing intestinal damage, reduces intestinal permeabil-
ity, and has a direct protective effect on the uncoupling of
mitochondrial oxidative phosphorylation caused by non-
steroidal anti-inflammatory drugs.11
At this time no effective medical therapy is available for
treatment of PSC. Various treatment strategies have been
evaluated in PSC and negative studies have been pub-
lished on glucocorticoids, budesonide, azathioprine, col-
chicine, cyclosporine, D-penicillamine, methotrexate,
tacrolimus, and pentoxifyllene12 and in a small series even
in combination with ursodeoxycholic acid (UDCA). In
the largest controlled trial conducted so far, UDCA at 13
to 15 mg/kg was not associated with any significant
changes in symptoms or in liver histology, whereas liver
function tests were improved during UDCA therapy.13 In
this study, however, a significant proportion of the pa-
tients already had advanced disease at baseline, and 34%
in the UDCA group had varices. In a recent study with 2
years’ follow-up, a higher dose of UDCA (20 mg/kg/d)
appears to have a beneficial effect on both liver histology
and cholangiographic findings at ERCP.14 Only one
small, uncontrolled long-term study using antibiotics in
the treatment of PSC has been published so far.15 The
study compared tetracycline, steroid therapy, and colec-
tomy in the management of PSC, demonstrating that
none of the strategies had a beneficial effect on the clinical
course of the disease.
In the present study, we evaluated the combination of
UDCA and MTZ in the treatment of PSC compared with
UDCA and placebo in a randomized, controlled 3-year
trial.
Patients and Methods
Patient Selection. Patients with suspected or known
PSC were screened for elevated liver enzymes (serum ala-
nine aminotransferase [ALT]  50 U/L, normal range
10-50 U/L and/or serum ALP  275 U/L, normal range
60-275 U/L), and diagnosis was confirmed via both liver
histology and ERCP (compatible with PSC) from Hel-
sinki, Tampere, and Turku University Hospitals, Fin-
land. All the participating hospitals were tertiary referral
centers. Patients aged 16 to 65 years were included in the
study if they had PSC documented via ERCP and histo-
logical analysis. Patients were excluded if they had (1)
end-stage liver disease with decompensation, which was
defined as ascites not easily controlled by diuretic therapy
(Child-Turcotte-Pugh C), (2) other coexisting liver dis-
eases, (3) suspected cholangiocarcinoma, (4) suspected or
documented malignancy, (5) recurrent ascending cholan-
gitis requiring antibiotic therapy, or (6) if they were preg-
nant. Previous use of UDCA was not an exclusion
criterion, but use and duration of UDCA therapy before
enrollment was noted and the patients on UDCA at base-
line continued the therapy, except for 6 patients who
stopped the medication 6 months before inclusion. The
study protocol conformed to the ethical guidelines of the
Declaration of Helsinki and was approved by the Helsinki
University Ethics Committee. All patients gave their writ-
ten informed consent.
Study Design. In this multicenter, randomized, dou-
ble-blind, placebo-controlled trial, the patients were ran-
domized either to UDCA and placebo (n  41) or
UDCA and MTZ (n  39). The sample size calculation
was based on our previous experience on the combination
therapy assuming that 30% improvement will be seen in
serum ALP, thus requiring 80 patients. The duration of
this pilot study of MTZ in PSC was planned for 36
months, because a shorter duration might not have dem-
onstrated any changes other than effect on liver function
tests. Randomization was done centrally with computer-
generated blocks, and patients were stratified according to
the type of inflammatory bowel disease, distribution of
PSC (intrahepatic or intra- and extrahepatic disease), and
possible previous colectomy.
UDCA at 15 mg/kg/d was administered in the form of
150-mg capsules (Adursal 150 mg, Leiras Finland, Hel-
sinki, Finland). MTZ at 600 to 800 mg/d was given in the
form of 200-mg tablets (Trikozol 200 mg, Orion Pharma,
Espoo, Finland), and doses were adjusted according to
body weight: 600 mg for patients weighing 75 kg or less
and 800 mg for patients weighing over 75 kg, or the same
number of placebo tablets.
Methods. A complete history and physical examina-
tion was performed upon entry into the study. ERCP was
performed within 6 months and liver biopsy within 12
months prior to enrollment. Abdominal Doppler ultra-
sound, esophago-gastroduodenoscopy with duodenal bile
sample, and colonoscopy were performed for every pa-
tient. Bile samples were obtained after stimulation with
cholecystokinin (1-2 U/kg intravenously) before the du-
odenal biopsies to analyze bile acid composition. Patients
on UDCA therapy before inclusion stopped UDCA be-
fore the duodenal bile sample was collected. Bile acids,
cholesterol, and phospholipids were analyzed from duo-
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denal bile aspirates via gas–liquid chromatography, and
molar concentrations were calculated.16 Serum levels for
full blood count, ALT, AST (normal range, 15-35 U/L),
ALP, bilirubin (20 mol/L), prothrombin time (70%-
130%), bile acids (8 mmol/L) albumin (36-48 g/L),
procollagen III N-terminal peptide (1.7-4.2 g/L), and
serum immunoglobulin G (6.8-15.0 g/L) and M (0.36-
2.59 g/L) were determined using routine laboratory
methods. Serum perinuclear antineutrophil cytoplasmic
antibody staining patterns and titers were determined via
indirect immunofluorescence employing ethanol and for-
malin-fixed human granulocytes.
Patients were followed up every 3 months with a symp-
tom questionnaire, clinical examination, and liver func-
tion tests. At the end of the study, ERCP, liver biopsy, and
abdominal ultrasound were repeated in addition to the
clinical evaluation, symptom questionnaire, and liver
function tests (including AST). Liver biopsies were eval-
uated by a sole pathologist who was blinded to the clinical
data and biopsy sequence. The liver biopsies were classi-
fied according to stage and grade, modified from Ludwig
et al.17 and Desmet et al.18 Stage reflects disease progres-
sion and morphological changes; grade reflects necroin-
flammatory activity. Stage was scored as follows:
normal  0; portal edema  1; periportal fibrosis  2;
septa formation and ductal loss  3; cirrhosis  4. Grade
scores were as follows: no inflammation  0; portal in-
flammation and pericholangitis  20% of areas  1;
portal inflammation and pericholangitis  20% of ar-
eas  2; mild interface inflammation (“piecemeal necro-
sis”)  3; marked interface inflammation  4. ERCP
findings were analyzed by two radiologists independently,
specialized in hepatobiliary diseases, and blinded to clin-
ical data and the order of examinations. Cholangiograms
were performed with balloon catheter occlusion whenever
possible, to ensure adequate filling pressure in intrahe-
patic peripheral branches. ERCP findings were classified
according to Craig et al.19 and by global assessment, with
findings graded as “improvement,” “no change,” or
“worsening.” The New Mayo Risk Score was calculated at
entry and at the end of the treatment period using the
revised PSC Mayo Risk Score20: risk  0.03  age (yr) 
0.54  loge(total bilirubin [mg/dL])  0.84  albumin
(g/dL)  0.54  loge(AST IU/L)  1.24  variceal
bleeding (yes  1; no  0).
The patients were treated for 36 months unless they
were referred for liver transplantation, developed a malig-
nancy or a decompensated liver cirrhosis, or died. Treat-
ment response was followed by: (1) clinical symptoms and
cholangitis episodes; (2) liver function tests (ALP, ALT,
AST, bilirubin, and albumin); (3) New Mayo Risk Score;
(4) liver histology; and (5) ERCP findings. Clinical symp-
toms: fatigue, fever, pruritus, and right upper quadrant
pain were scored as follows: 0  absent; 1  mild; 2 
moderate; 3  severe. After 36 months, MTZ/placebo
was stopped and patients were followed up for at least 12
weeks afterward.
Stastitical Analysis. Statistical analyses were con-
ducted with NCSS 2000 software (Kaysville, UT). Re-
sults between groups are expressed as the mean  SE.
Two-sample t tests or Wilcoxon rank sum tests served to
examine differences between groups. ANOVA deter-
mined the effect of therapy on liver histology and ERCP
findings.
Results
Clinical Data. Eighty patients fulfilling the entry
criteria were randomized to either UDCA and placebo
(n  41) or UDCA and MTZ (n  39) (Fig. 1).
Baseline clinical data are presented in Table 1. No
significant differences appeared between treatment
arms. One patient had small-duct PSC with typical
histology but normal ERCP. In total, half of the pa-
tients had no or only mild symptoms (sum score of
symptoms: fatigue, fever, pruritus, right upper quad-
rant pain  1) at entry. Of the study population, 81%
had concomitant inflammatory bowel disease, most
frequently ulcerative colitis (80%). At the end of the
study, 75% of UDCA/placebo patients and 79% of
those on UDCA/MTZ were asymptomatic; the differ-
ence was considered insignificant. Only 2 patients in
both groups had varices at baseline endoscopy. Three
patients had overlapping syndromes of autoimmune
hepatitis and PSC diagnosed by positive smooth mus-
cle antibodies, elevation of serum immunoglobulin G,
and typical histology with interface inflammation in
addition to typical ERCP findings. Two of these pa-
Fig. 1. The effect of UDCA/placebo or UDCA/MTZ on mean serum ALP
levels during 36 months. After 36 months, all patients were placed on
UDCA monotherapy (15 mg/kg/d). S-ALP, serum alkaline phosphatase;
UDCA, ursodeoxycholic acid; MTZ, metronidazole.
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tients had a flare of autoimmune hepatitis with signif-
icant elevation of serum ALT levels and were treated
with prednisone. Both patients were in the UDCA/
placebo group. During the treatment period, 3 patients
in the UDCA/placebo group underwent liver trans-
plantation: 1 at 6 months, and 2 at 16 months. In the
UDCA/MTZ group, 2 patients developed cholangio-
carcinoma diagnosed at 15 and 34 months, and 1
patient discontinued the study because of liver trans-
plantation.
Laboratory Values. Baseline levels and changes in
liver biochemistry and the Mayo Risk Score after 3 years
of treatment are summarized in Table 2. At entry, the
treatment groups were comparable with regard to liver
function tests and risk score. Serum immunoglobulin lev-
els were similar at baseline, and no differences were found
during the treatment period. During therapy, ALP levels
dropped in both groups—more significantly in the
UDCA/MTZ group—and remained lower throughout
the study period (Fig. 1). After 36 months of therapy,
when MTZ or placebo was stopped and patients contin-
ued only on UDCA monotherapy, the difference between
study groups disappeared. ALT and AST were signifi-
cantly improved in both groups, and bilirubin values
(which were within normal range at entry) remained un-
changed. Serum procollagen III N-terminal peptide levels
were similar in both groups and did not change markedly
during therapy. In patients treated with UDCA/MTZ,
however, both the New Mayo Risk Score and serum ALP
levels decreased (P  .05) compared with the UDCA/
placebo group, and the mean ALP value even normalized
(see Table 2). The molar percentage of UDCA rose mark-
edly from 2.6% to 51.3% in the UDCA/placebo group
and from 1.1% to 48.0% in the UDCA/MTZ group,
though this change demonstrated no differences between
groups.
Histology. Adequate liver biopsies at entry and at 36
months were available for comparative analysis from 36
patients in the UDCA/placebo group and from 32 pa-
tients in the UDCA/MTZ group. The results are pre-
sented in Tables 3 and 4. In biopsies at baseline, no
significant differences existed between the treatment arms
for stage or grade (see Table 3). Improvement of stage was
Table 1. Clinical Characteristics of the Study Patients at
Baseline
Characteristics Total UDCA  Placebo UDCA  MTZ
No. 80 41 39
Females, % 48 42 51
Age, yr 39  2 41  2 37  2
Age at diagnosis, yr 36  2 37  2 34  2
Duration of PSC, yr 3.7  0.7 3.7  0.7 3.7  0.6
Distribution of PSC
Intrahepatic only, % 51 52 48
Varices 4 2 2
S-pANCA positive, % 58 58 57
Concomitant IBD, % 81 87 79
Ulcerative colitis, % 80 84 76
Crohn’s disease, % 15 13 17
Indeterminate colitis,
% 5 3 7
Previous use of UDCA
No., % 22 (28) 8 (20) 14 (36)
Range, mo 1–60 7–60 1–41
Concomitant medication
5-aminosalicylates 52 28 24
Azathioprine 4 2 2
NOTE. Data are presented as the mean  SE. No statistical differences were
noted between the treatment groups.
Abbreviations: S-pANCA, serum perinuclear anti-neutrophil cytoplasmic anti-
bodies; IBD, inflammatory bowel disease.
Table 2. Laboratory Data for Study Patients
Variable













ALP (U/L) 567  63 313  33†† 214  50 643  65 253  34†† 337  54*
AST (U/L) 81.8  13.2 48.0  5.2†† 28.0  10.4 79.0  7.1 45.6  4.8†† 32.4  7.4
ALT (U/L) 126  18 59  9†† 71  15 140  19 49  9†† 95  17
GGT (U/L) 519  91 168  49†† 358  71 584  92 214  53†† 394  82
Total bilirubin (mol/L) 15.8  1.5 15.0  1.2 0.8  1.3 16.1  1.6 13.5  1.1 1.0  1.0
Bile acids (mmol/L) 26.5  8.5 21.1  5.2 10.5  5.9 11.6  1.9 29.2  7.9 17.4  6.4
Albumin (mg/L) 40.5  0.7 41.0  0.8 0.2  0.7 40.3  0.7 42.0  0.8 1.4  0.9
Prothrombin time (s) 104  5 107  6 5  5 112  5 98  7 12  6**
B platelets  109/L 247  12 241  11 0.2  0.7 273  16 247  15 1.4  0.9
PIIINP (g/L) 4.6  0.3 4.0  0.3 0.6  0.3 4.7  0.3 4.6  0.3 0.1  0.4
Biliary UDCA (%) 2.6  0.5 51.3  2.1†† 48.5  2.0 1.1  0.3 48.0  2.6†† 46.2  3.1
New Mayo Risk Score 0.15  0.11 0.21  0.10 0.06  0.08 0.18  0.11 0.50  0.13†† 0.32  0.10*
NOTE. Data are presented as the mean  SE.
Abbreviations: GGT, -glutamyltransferase; PIIINP, procollagen III N-terminal peptide.
*P  .05, **P  .01; differences between treatment groups.
††P  .01; differences from baseline.
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seen in 34% of patients in the UDCA/MTZ group, sig-
nificantly more often than in the UDCA/placebo group
(P  .047) (see Table 4). Either no change or improve-
ment of stage was seen in 69% of patients treated with
UDCA/placebo and in 62% of patients on UDCA/MTZ,
showing no difference between groups. Progression in
stage of liver histology was seen in 31% to 38% of patients
in the UDCA/placebo and UDCA/MTZ groups, respec-
tively. Grade showed improvement during UDCA/MTZ
therapy in 34.4% of study subjects, whereas only 14% of
those undergoing UDCA monotherapy demonstrated
improvement, significantly less than in the combination
group (P  .014). Improvement or no sign of progression
in grade was evident in 72% of patients on UDCA/MTZ
therapy but only in 58% on UDCA/placebo therapy. The
mean grade decreased more significantly in the combina-
tion group (0.18  0.18) compared with patients
treated with UDCA alone (0.39  0.15) (P  .009).
ERCP Findings. ERCP findings with adequate filling
at baseline and at 36 months were available for compara-
tive analysis for 48 patients, 23 of whom were in the
UDCA/MTZ group. In a global assessment, improve-
ment or no change was seen in 68% of patients in the
UDCA/placebo group and in 83% of patients in the com-
bination group. Worsening of cholangiographic findings
were seen in 32% of the UDCA/placebo patients and
17% of the UDCA/MTZ patients. Differences between
groups did not reach significance.
Side Effects. Both UDCA and MTZ therapy were
well tolerated with no serious side effects (side effects are
summarized in Table 5). Seven patients in the UDCA/
placebo group reported side effects, as did 18 patients in
the UDCA/MTZ group (P  .05). Although the dose of
study medication was reduced temporarily in 5 cases,
none of the patients discontinued the study medication
because of side effects.
Discussion
In this randomized, placebo-controlled trial of antibi-
otics—in addition to UDCA—in the treatment of PSC, a
significant decrease in serum ALP, ALT, AST, and -glu-
tamyltransferase activity was seen in both treatment arms.
Combining MTZ with UDCA improved serum ALP val-
ues significantly and the New Mayo Risk Score even fur-
ther. In the UDCA/MTZ group, more patients had an
improvement of both stage and grade of liver histology,
and the decrease of the mean grade was greater (P 
.009). However, no differences between groups in pa-
tients with either improvement or no change in stage or
grade were seen. In ERCP findings, the proportion of
patients with either improvement or no progression was
83% of those on UDCA/MTZ therapy compared with
68% of those on monotherapy, showing a trend favoring
combination therapy.
Because the etiopathogenesis of PSC is unknown, no
specific therapy is currently available. Moreover, there are








0 (normal) 10 (27) 7 (21)
1 (portal edema) 7 (19) 5 (15)
2 (periportal fibrosis) 15 (41) 13 (38)
3 (septal formation and ductal loss) 3 (8) 9 (26)
4 (cirrhosis) 2 (5) 0 (0)
Grade, n (%)
0 (no inflammation) 5 (14) 10 (29)
1 (portal inflammation  20% of areas) 13 (36) 6 (18)
2 (portal inflammation  20% of areas) 7 (36) 5 (15)
3 (mild interface inflammation) 6 (17) 8 (23)
4 (marked interface inflammation) 6 (14) 5 (15)
NOTE. No statistically significant differences were noted between groups.
Table 4. Effect of Therapy on Liver Histology (Stage and





(n  32) P Value
Stage, n (%)
Improvement 5 (14.0) 11 (34.4) .047
No change 20 (55.5) 9 (28.1) .022
Worsening 11 (30.5) 12 (37.5) NS
Grade, n (%)
Improvement 6 (16.6) 14 (43.8) .014
No change 15 (41.7) 9 (28.1) NS
Worsening 15 (41.7) 9 (28.1) NS
Abbreviation: NS, not significant.
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Diarrhea/loose stools 1 5
Dizziness 1
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no tools for screening and diagnosing the disease early
enough (i.e., when it is amenable to treatment), well be-
fore irreversible strictures, fibrosis, and cirrhosis have de-
veloped. Most previous studies have evaluated the effect
of immunosuppressive agents in PSC (e.g., prednisone,
budesonide, azathioprine, methotrexate, and penicilla-
mine) with completely negative or very limited ef-
fects,21–30 suggesting that immunological factors probably
play little or no role in the pathogenesis of PSC by the
time marked strictures or cirrhosis have developed. PSC is
a progressive disease leading to obstruction of bile ducts
and cholestasis, which in turn leads to increased endo-
toxin levels in the portal space and activation of Kupffer
cells and macrophages. UDCA has been shown to dis-
place hydrophobic endogenous bile acids associated with
increased cell membrane fluidity and permeability and
with increased secretion of bile acids and other organic
compounds.31 Moreover, UDCA has been shown to be
immunomodulatory,32 and in primary biliary cirrhosis it
reduces the overexpression of hepatocellular and biliary
expression of major histocompatibility complex Class I
and II molecules,33,34 unlike cyclosporin or corticoste-
roids.35
In PSC, UDCA therapy at 13 to 15 mg/kg/d has been
associated with significant improvement in biochemical
test results13,36 but has not been shown to have any effect
on symptoms, liver histology, or time to transplanta-
tion.13 A dosage of 20 mg/kg/d UDCA14 used in 13 pa-
tients for 2 years did not affect symptoms compared with
placebo, but 2 patients (15%) showed marked improve-
ment in cholangiographic appearance and 3 patients
(27%) showed similar improvement in histological in-
flammatory score. Another pilot study37 of 30 patients
treated with 25 to 30 mg/kg/d UDCA for 1 year im-
proved the New Mayo Risk Score and AST and ALP
levels significantly compared with a standard dose but did
not have any influence on bilirubin. In primary biliary
cirrhosis, doubling the dosage of UDCA to 28 to 32 mg/
kg/d did not benefit most patients not responding to a
dosage of 13 to 15 mg/kg/d.38 We used a standard dosage
of 15 mg/kg/d UDCA, because at the time of the study
only small studies using UDCA 10 to 15 mg/kg/d had
been published, some of them suggesting beneficial effects
even on histology.36,39
In our study, 20% of patients in total were already on
UDCA before the study, and the aim was to evaluate the
possible additional effect of MTZ on the treatment re-
sponse of UDCA, so we did not have a placebo group. A
recent Scandinavian study demonstrated that patients
with PSC who were treated with UDCA while on a wait-
ing list for liver transplantation had significantly fewer
cholangiocarcinomas than patients who did not receive
UDCA therapy, suggesting that even a standard dose of
UDCA may have a positive effect on the clinical outcome
of the disease.40 Very few studies have actually evaluated
the effect of UDCA on ERCP changes,3,14,41 one of them
demonstrating that it does not prevent major bile duct
occlusion even during therapy lasting up to 13 years,41
making it questionable that a higher dose can really im-
prove cholangiographic appearance within 2 years.14 In
the present study, we excluded patients with end-stage
liver disease, and half of the patients were actually asymp-
tomatic and had intrahepatic disease of only 3.4 years’
mean duration (range, 0-18 years). In liver histology,
stage was normal in 28% of patients in both groups,
whereas only 2 patients in the UDCA/placebo group and
3 in the UDCA/MTZ group had cirrhosis at liver biopsy.
Our patient population represents a more favorable op-
portunity to evaluate medical therapy for PSC than in
most previous studies, where up to 23% to 25% of pa-
tients had cirrhosis.13,36 UDCA therapy significantly im-
proved liver biochemistry in both groups in accordance
with previous findings.13,14,36 Marked inflammation
(grades 3-4), seen in 31% of patients in the UDCA/pla-
cebo group and in 38% of patients in the UDCA/MTZ
group, suggests a chronically active disease process. The
slight improvement in liver histology both in stage and in
grade seen in UDCA/MTZ therapy versus UDCA alone
would suggest an anti-inflammatory effect of MTZ.
However, the effect of MTZ on liver histology during 3
years’ therapy was only marginal regarding the number of
patients with improvement or no progression, because no
difference was found between groups. Unfortunately, we
only had adequate comparable biopsies from 32 patients
in the UDCA/MTZ group, and the difference between
groups did not reach statistical significance. PSC is a seg-
mental disease, and a single liver biopsy may be associated
with a significant sampling error.42 The role of liver bi-
opsy in PSC has recently been challenged,43 suggesting
that it does not affect management. The present study
demonstrates, however, that marked inflammation is
present in a significant proportion of patients, which can
be affected by the combination of MTZ and UDCA.
The follow-up of disease progression in PSC is prob-
lematic because there is poor correlation between ERCP
findings, liver histology, and liver biochemistry.14 We in-
cluded the control ERCP in the study protocol because
classification and staging of cholangiographic abnormali-
ties has been shown to have prognostic value.44 In those
patients in whom comparable examinations with ade-
quate filling were available, a trend showing either im-
provement or no progression of the disease was seen in the
UDCA/MTZ group compared with those on UDCA
monotherapy. However, no differences were evident dur-
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ing 3 years of therapy between the groups regarding referrals
for liver transplantation, progression to decompensated liver
cirrhosis, development of malignancy, or death. Follow-up
for 3 years is too short a period to expect differences in such
parameters, especially in a patient population with a disease
that is not associated with cirrhosis.
What is the rationale behind MTZ therapy in PSC?
MTZ has a beneficial effect on intestinal inflammation
and reduces colonic permeability11 to bacterial endotox-
ins. It may inhibit endotoxin-induced tumor necrosis fac-
tor alpha production, activation of Kupffer cells and
portal tract macrophages, and secretion of chemokines
and cytokines by biliary epithelial cells. This leads to at-
tenuation of inflammation in the liver, which is reflected
by improvement in histology and normalization of liver
function tests. MTZ therapy as such seems to have no
effect on biliary secretion of UDCA, so the effects of
MTZ on PSC are apparently not caused by changes in the
metabolism of UDCA, because no differences were seen
between UDCA contents in duodenal bile. Patients on
UDCA/MTZ had significantly more side effects (53%)
than patients on UDCA monotherapy; however, they
were mostly mild, and none of them was severe enough to
require cessation of therapy.
In conclusion, the addition of MTZ to UDCA therapy
significantly improved liver function tests and reduced
the New Mayo Risk Score. For both stage and grade, the
number of patients with improved histology was higher in
the combination group, with a significant reduction of
mean grade (P  .009), and there was also a trend toward
inhibition of progression of ERCP changes. To improve
treatment results in PSC, we must know more about the
pathogenic mechanisms and must aim for diagnosis at
earlier stages, before irreversible strictures and fibrosis
have developed. Meanwhile, the treatment target is to
have UDCA attenuate the inflammatory process and pre-
vent both further damage by endogenous toxic bile acids
to the biliary tree and further development of cholangio-
carcinoma. Longer follow-up studies using the combina-
tion of MTZ and a higher dose of UDCA are needed to
demonstrate their effect on major end points such as cir-
rhosis, liver transplantation, development of cholangio-
carcinoma, and death.
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